Project Oncology® ReachMD
-
- Science
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
-
Indications to Switch Therapies for Myelofibrosis Patients
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Justin Arnall, PharmD, BCOP, CPP
Guest: Jerry L. Spivak MD, MACP
While managing patients with myelofibrosis, there are certain indications that it may be time to switch therapies. And working with your patient will help with a timely and seamless transition. To learn more about these best practices, join Dr. Charles Turck as he speaks with Dr. Justin Arnal, Clinical Coordinator of Hematology at Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, and Dr. Jerry Spivak, Emeritus Professor Medicine at the Johns Hopkins University School of Medicine. -
Managing Myelofibrosis with a Patient-Centered Approach
Guest: Justin Arnall, PharmD, BCOP, CPP
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jerry L. Spivak MD, MACP
After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to select the best intervention. Having a personalized approach to treatment and management could have a beneficial impact on the overall quality of life of your patient. Tune in with Dr. Charles Turck for insights and experiences from real-life patient cases with Dr. Justin Arnal, Clinical Coordinator of Hematology at Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, and Dr. Jerry Spivak, Emeritus Professor of Medicine at Johns Hopkins University School of Medicine. -
Anemia and Myelofibrosis: Optimizing Diagnosis, Treatment, and Management Strategies
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Prithviraj Bose, MD
Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. -
Exploring the Significant Presence of Anemia in Myelofibrosis
Host: Jennifer Caudle, DO
Guest: Jason Tremblay
Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with ensuring we’re using the best therapeutic strategies. Learn more with Dr. Jennifer Caudle as she speaks with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. -
Navigating Myelofibrosis Treatment Complexities to Optimize Care
Host: Jennifer Caudle, DO
Guest: Jason Tremblay
Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even be rare to see patients who experience myelofibrosis the same. So to take a deep dive into the treatment paradigm of this disease is Dr. Jennifer Caudle who will be speaking with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. -
B-Cell Lymphoma Care: Overcoming Challenges in the Second-Line Setting
Guest: Matthew Lunning, DO, FACP
It’s not uncommon for patients with B-cell lymphoma to have relapsed or refractory disease, making it essential to know how to approach their second-line treatment. Unfortunately, many challenges and unmet needs exist in this setting, which is why Dr. Matthew Lunning is here to discuss those challenges as well as the novel therapies that are helping us overcome them. Dr. Lunning is an Associate Professor in the Division of Hematology and Oncology at the University of Nebraska Medical Center.